Edition:
United States

Aldeyra Therapeutics Inc (ALDX.OQ)

ALDX.OQ on NASDAQ Stock Exchange Capital Market

4.45USD
4:00pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$4.45
Open
$4.45
Day's High
$4.45
Day's Low
$4.30
Volume
4,245
Avg. Vol
17,644
52-wk High
$8.17
52-wk Low
$3.80

Latest Key Developments (Source: Significant Developments)

Aldeyra Therapeutics presents noninfectious anterior uveitis Phase 2 clinical trial data
Wednesday, 17 May 2017 08:00am EDT 

May 17 (Reuters) - Aldeyra Therapeutics Inc :Presents noninfectious anterior uveitis Phase 2 clinical trial data.Aldeyra Therapeutics - data demonstrated ADX-102 activity comparable to standard-of-care topical ocular corticosteroids in reducing anterior chamber cell count.Says unlike corticosteroid therapy, ADX-102 did not increase intraocular pressure.Aldeyra Therapeutics - results from Phase 3 trial of topical ADX-102 in NAU expected to be announced in second half of 2018.Aldeyra therapeutics - results from co's Phase 2A dry eye syndrome clinical trial, expected in Q3 of this year.  Full Article

Aldeyra Therapeutics says results of late stage trial expected in H2 2018
Thursday, 27 Apr 2017 08:00am EDT 

April 27 (Reuters) - Aldeyra Therapeutics Inc :Aldeyra therapeutics announces first patient enrolled in noninfectious anterior uveitis phase 3 clinical trial.Aldeyra therapeutics inc- results of phase 3 trial are expected in second half of 2018.  Full Article

Aldeyra Therapeutics receives orphan drug designation from FDA
Thursday, 20 Apr 2017 08:00am EDT 

April 20 (Reuters) - Aldeyra Therapeutics Inc ::Aldeyra Therapeutics Inc receives orphan drug designation from the U.S. Food And Drug Administration for ADX-102 in sjögren-larsson syndrome.Aldeyra Therapeutics Inc- FDA granted Aldeyra's novel compound ADX-102 orphan drug designation for treatment of congenital ichthyosis.Aldeyra Therapeutics Inc- pivotal phase 3 study is expected to begin later this year.  Full Article

Aldeyra Therapeutics expects board size to be reduced
Thursday, 6 Apr 2017 04:34pm EDT 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics - on April 3, C. Boyd Clarke, chairman of board notified co's board that he does not intend to run for re-election - sec filing .Aldeyra Therapeutics - effective as of co's 2017 annual stockholder meeting, size of board expected to be reduced from eight to seven members -sec filing.  Full Article

Sphera Funds reports 6.17 pct passive stake in Aldeyra Therapeutics as of Feb 14
Tuesday, 21 Feb 2017 06:20am EST 

Aldeyra Therapeutics Inc :Sphera Funds Management Ltd reports 6.17 percent passive stake in Aldeyra Therapeutics Inc as of Feb 14 - sec filing.  Full Article

Aldeyra Therapeutics announces patient enrollment in conjunctivitis trial
Tuesday, 7 Feb 2017 08:00am EST 

Aldeyra Therapeutics Inc :Aldeyra therapeutics announces first patient enrolled in allergic conjunctivitis phase 2b clinical trial.  Full Article

Aldeyra Therapeutics Q3 loss per share $0.38
Monday, 14 Nov 2016 07:30am EST 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics Inc - Phase III vehicle-controlled trial in noninfectious anterior uveitis, expected to be initiated in first half of 2017 . Q3 loss per share $0.38 . Aldeyra therapeutics announces third quarter 2016 financial results .Q3 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S.  Full Article

Aldeyra Therapeutics reports Q2 loss per share $0.41
Wednesday, 10 Aug 2016 07:00am EDT 

Aldeyra Therapeutics Inc : Aldeyra Therapeutics announces second quarter 2016 financial results and provides corporate update . Q2 loss per share $0.41 .Q2 earnings per share view $-0.44 -- Thomson Reuters I/B/E/S.  Full Article

Aldeyra Therapeutics proposes public offering of common stock
Wednesday, 25 May 2016 04:01pm EDT 

Aldeyra Therapeutics : Aldeyra Therapeutics Inc proposes public offering of common stock .Net proceeds to be used for continued development of NS2 and other product candidates, including further clinical testing of NS2.  Full Article

Aldeyra Therapeutics announces positive results from Phase II clinical trials
Monday, 9 May 2016 07:30am EDT 

Aldeyra Therapeutics Inc : NS2 generally well tolerated; no serious adverse events, consistent with previous Phase I and Phase II clinical trials . No statistical differences among all groups in any clinical endpoint, including anterior chamber cell count and ocular flare . Aldeyra therapeutics announces positive results from phase II clinical trial in subjects with noninfectious anterior uveitis .Quarterly loss per share $0.51.  Full Article

More From Around the Web

BRIEF-Aldeyra Therapeutics reports Q1 loss per share $0.37

* Aldeyra Therapeutics provides corporate update and announces first quarter 2017 financial results